The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
Open accessAbstract
Background: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer (NSCLC). Patients and Methods: We conducted a retrospective study of patients who received nivolumab monotherapy at Sendai Kousei Hospital (n = 70). The patients were categorized into two groups based on the incidence of irAEs: those with irAEs (irAE group) or those without (non-irAE group). Treatment efficacy was evaluated in each group. The patients were further categorized into responders and nonresponders, and predictive factors of treatment response were determined. Results: The objective response rate was 57% in the irAE group versus 12% in the non-irAE group. Median progression-free survival was 12.0 months in the irAE versus 3.6 months in the non-irAE group. The incidence of both irAEs and pre-existing antithyroid antibody was significantly higher in responders than in nonresponders. Multivariate analysis identified incidence of irAEs and pre-existing antithyroid antibody as an independent predictor of treatment response. Conclusion: Objective response rate and progression-free survival were significantly better in the irAE than in the non-irAE group in patients with advanced NSCLC treated with nivolumab monotherapy. The development of irAEs was associated with clinical efficacy, and the presence of pre-existing antithyroid antibody might be correlated with treatment response to nivolumab monotherapy. Implications for Practice: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study evaluted whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer. Results showed that the objective response rate and progression-free survival were significantly better in the patients who developed irAEs than in the patients who did not develop irAEs, and the incidence of irAEs and positivity for antithyroid antibody at pretreatment were independent predictors of treatment response of nivolumab monotherapy. Therefore, the development of irAEs predicts clinical benefit and suggests that cautious management of irAEs can lead to achieving maximum clinical benefit from nivolumab monotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Across disease sites, patients who experience IRAEs while on therapy with anti-PD-1 and anti-PD-L1 antibodies have been documented to experience improved outcomes as measured by overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) [13–20].”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [15]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,876
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Hussaini, S. M. Q., Chehade, R., Boldt, G., Raphael, J., Blanchette, P., Vareki, S. M., & Fernandes, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102134 · Cited by 412
Şahin, İ. H., Akce, M., Alese, O. B., Shaib, W. L., Lesinski, G. B., El‐Rayes, B. F., & Wu, C. S.-Y. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 404
Radiation-induced lung injury: current evidence
Arroyo‐Hernández, M., Maldonado, F., Lozano-Ruiz, F. J., Munoz-Moñtano, W., Báez, M. N., & Arrieta, O. G. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01376-4 · Cited by 384
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352
Self-citationAutoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 250
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0618 · Cited by 208
Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F., & Del Vecchio, M. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2819-x · Cited by 202
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Abu‐Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S. H., Otterson, G. A., Kendra, K. L., Ricciuti, B., Chiari, R., Giglio, A. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00320 · Cited by 201
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Nishio, M., Mok, T. S. K., Reck, M., Finley, G. G., Kaul, M. D., Yu, W., Paranthaman, N., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7711 · Cited by 191
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
Cortellini, A., Chiari, R., Ricciuti, B., Metro, G., Perrone, F., Tiseo, M., Bersanelli, M., Bordi, P., Santini, D., Giusti, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.006 · Cited by 181
Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R. S., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M. L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 182
Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., Honma, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6150-y · Cited by 143
on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0579-z · Cited by 140
Dall’Olio, F. G., Rizzo, A., Mollica, V., Massucci, M., Maggio, I., & Massari, F. (2020) · Immunotherapy · doi:10.2217/imt-2020-0179 · Cited by 140
Duma, N., Abdel-Ghani, A., Yadav, S., Hoversten, K. P., Reed, C. T., Sitek, A. N., Enninga, E. A. L., Paludo, J., Aguilera, J. V., Leventakos, K., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0094 · Cited by 136
Johkoh, T., Lee, K. S., Nishino, M., Travis, W. D., Ryu, J. H., Lee, H. Y., Ryerson, C. J., Franquet, T., Bankier, A. A., Brown, K. K., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2020.11.027 · Cited by 128
Johkoh, T., Lee, K. S., Nishino, M., Travis, W. D., Ryu, J. H., Lee, H. Y., Ryerson, C. J., Franquet, T., Bankier, A. A., Brown, K. K., et al. (2021) · Radiology · doi:10.1148/radiol.2021203427 · Cited by 128
Petrelli, F., Grizzi, G., Ghidini, M., Ghidini, A., Ratti, M., Panni, S., Cabiddu, M., Ghilardi, M., Borgonovo, K., Parati, M. C., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000300 · Cited by 129
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 121
Fukihara, J., Sakamoto, K., Koyama, J., Ito, T., Iwano, S., Morise, M., Ogawa, M., Kondoh, Y., Kimura, T., Hashimoto, N., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.006 · Cited by 114
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 103
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barré, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.036 · Cited by 105
Vitale, E., Rizzo, A., Maistrello, L., Güven, D. C., Massafra, R., Mollica, V., Monteiro, F. S. M., Santoni, M., & Massari, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-71746-z · Cited by 104
Zhai, X., Zhang, J., Tian, Y., Li, J., Wang, J., Guo, H., & Zhu, H. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0102 · Cited by 99
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 100
Hsiehchen, D., Watters, M. K., Lü, R., Xie, Y., & Gerber, D. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11519 · Cited by 89
Dykema, A. G., Zhang, J., Cheung, L. S., Connor, S. C., Zhang, B., Zeng, Z., Cherry, C., Li, T., Caushi, J. X., Nishimoto, M., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg1487 · Cited by 88
Matsuoka, H., Hayashi, T., Takigami, K., Imaizumi, K., Shiroki, R., Ohmiya, N., Sugiura, K., Kawada, K., Sawaki, A., Maeda, K., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07142-3 · Cited by 81
Kitagawa, S., Hakozaki, T., Kitadai, R., & Hosomi, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13483 · Cited by 81
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Maillet, D., Corbaux, P., Stelmes, J., Dalle, S., Locatelli-Sanchez, M., Perier‐Muzet, M., Duruisseaux, M., Kiakouama-Maleka, L., Freyer, G., Boespflug, A. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.017 · Cited by 79
Shimozaki, K., Sukawa, Y., Beppu, N., Kurihara, I., Suzuki, S., Mizuno, R., Funakoshi, T., Ikemura, S., Tsugaru, K., Togasaki, K., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s247554 · Cited by 77
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 77
Anderson, R., Theron, A. J., & Rapoport, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02254 · Cited by 73
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
Cortellini, A., Verna, L., Porzio, G., Bozzetti, F., Palumbo, P., Masciocchi, C., Cannita, K., Parisi, A., Brocco, D., Tinari, N., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12965 · Cited by 66
Cortellini, A., Buti, S., Agostinelli, V., & Bersanelli, M. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.003 · Cited by 62
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Xu, S., Lai, R., Zhao, Q., Zhao, P., Zhao, R., & Guo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.794099 · Cited by 59
Komiya, K., Nakamura, T., Abe, T., Ogusu, S., Nakashima, C., Takahashi, K., Kimura, S. H., & Sueoka‐Aragane, N. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13149 · Cited by 59
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 57
Self-citationKfoury, M., Najean, M., Lappara, A., Voisin, A.-L., Champiat, S., Michot, J., Laghouati, S., Robert, C., Besse, B., Soria, J., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102452 · Cited by 58
Namikawa, T., Yokota, K., Tanioka, N., Fukudome, I., Iwabu, J., Munekage, M., Uemura, S., Maeda, H., Kitagawa, H., Kobayashi, M., et al. (2020) · Surgery Today · doi:10.1007/s00595-020-02048-w · Cited by 58
Riudavets, M., Mosquera, J., García‐Campelo, R., Serra-López, J., Anguera, G., Gallardo, P., Sullivan, I., Joaquín, A. B., del Carpio, L. P., Barnadas, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01677 · Cited by 55
Isono, T., Kagiyama, N., Takano, K., Hosoda, C., Nishida, T., Kawate, E., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kurashima, K., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13736 · Cited by 54
Egami, S., Kawazoe, H., Hashimoto, H., Uozumi, R., Arami, T., Sakiyama, N., Ohe, Y., Nakada, H., Aomori, T., Ikemura, S., et al. (2021) · Journal of Cancer · doi:10.7150/jca.53242 · Cited by 52
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50
Sugano, T., Seike, M., Saito, Y., Kashiwada, T., Terasaki, Y., Takano, N., Hisakane, K., Takahashi, S., Tanaka, T., Takeuchi, S., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13364 · Cited by 50
Park, R., Lopes, L., & Saeed, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02397-5 · Cited by 50
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J., Guimbaud, R., Meyer, N., Mazières, J., & Alric, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682383 · Cited by 47
Fujimoto, D., Miura, S., Yoshimura, K., Wakuda, K., Oya, Y., Yokoyama, T., Yokoi, T., Asao, T., Tamiya, M., Nakamura, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.016 · Cited by 46
Self-citationBai, R., Chen, N., Chen, X., Li, L., Song, W., Li, W., Zhao, Y., Zhang, Y., Han, F., Lyu, Z., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0052 · Cited by 50
Li, L., Liu, Y., Chen, C., Wei, A., & Li, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190001 · Cited by 45
Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond
Reuss, J. E., Suresh, K. S., & Naidoo, J. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00920-z · Cited by 44
Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Hirano, K., Matsumoto, H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.003 · Cited by 43
Baldini, E., Lunghi, A., Cortesi, E., Turci, D., Signorelli, D., Stati, V., Melotti, B., Ricciuti, B., Frassoldati, A., Romano, G., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.014 · Cited by 43
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41
Daban, A., Gonnin, C., Phan, L., Saldmann, A., Granier, C., Louët, A. L., Beller, C. L., Pouchot, J., Weiss, L., Tartour, É., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204754 · Cited by 42
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Middha, P., Thummalapalli, R., Betti, M. J., Yao, L., Quandt, Z., Balaratnam, K., Bejan, C. A., Cardenas, E. R., Falcon, C. J., Faleck, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44512-4 · Cited by 42
Baker, M. L., Yamamoto, Y., Perazella, M. A., Dizman, N., Shirali, A. C., Hafez, N., Weinstein, J. N., Simonov, M., Testani, J. M., Kluger, H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004421 · Cited by 42
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Ao, Y.-Q., Gao, J., Wang, S., Jiang, J.-H., Deng, J., Wang, H., Xu, B., & Ding, J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01772-4 · Cited by 42
George, S., Bell, E. J., Zheng, Y., Kim, R., White, J. C., Devgan, G., Smith, J., Lal, L. S., Engel-Nitz, N. M., & Liu, F. X. (2021) · The Oncologist · doi:10.1002/onco.13812 · Cited by 40
Alves, A., Dias, M., Campainha, S., & Barroso, A. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3525 · Cited by 41
Shi, Y., Fang, J., Zhou, C., Liu, A., Wang, Y., Meng, Q., Ding, C., Ai, B., Gu, Y., Yao, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14274 · Cited by 37
Hu, W., Zhang, Q., Zhang, Z., He, X., Zhou, M., Guo, Y. M., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1112409 · Cited by 38
Wu, F., Zhang, Z., Wang, M., Ma, Y., Verma, V., Xiao, C., Zhong, T., Chen, X., Wu, M., Yu, J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.005 · Cited by 38
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Fan, Y., Geng, Y., Shen, L., & Zhang, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0735-3 · Cited by 35
Imaging features of toxicities associated with immune checkpoint inhibitors
Gosangi, B., McIntosh, L., Keraliya, A. R., Irugu, D. V. K., Baheti, A., Khandelwal, A., Thomas, R., & Braschi‐Amirfarzan, M. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100434 · Cited by 36
Haryal, A., Townsend, M. J., Baskaran, V., Srivoleti, P. D., Giobbie‐Hurder, A., Sack, J., Isidro, R. A., LeBoeuf, N. R., Buchbinder, E. I., Hodi, F. S., et al. (2022) · Cancer · doi:10.1002/cncr.34543 · Cited by 34
Fiala, O., Šorejs, O., Šustr, J., Kučera, R., Topolčan, O., & Fínek, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14063 · Cited by 34
Chen, M., Li, Q., Xu, Y., Zhao, J., Zhang, L., Wei, L., Zhong, W., & Wang, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13488 · Cited by 33
Yoshikawa, Y., Imamura, M., Yamauchi, M., Hayes, C. N., Aikata, H., Okamoto, W., Miyata, Y., Okada, M., Hattori, N., Sugiyama, K., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10327-7 · Cited by 37
Chen, X., Nie, J., Dai, L., Hu, W., Zhang, J., Han, J., Ma, X., Tian, G., Han, S., Wu, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.607531 · Cited by 32
Ikeda, T., Ishihara, H., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Takagi, T., Iizuka, J., Hashimoto, Y., Ishida, H., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.012 · Cited by 32
Diabetes mellitus induced by immune checkpoint inhibitors
Zheng, Z., Liu, Y., Yang, J., Tan, C., Zhou, L., Wang, X., Li, X., Zhang, S., Chen, Y., & Liu, X. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3366 · Cited by 32
Ando, T., UEDA, A., Ogawa, K., Motoo, I., Kajiura, S., Nakajima, T., Hirano, K., Okumura, T., Tsukada, K., Hara, T., et al. (2021) · In Vivo · doi:10.21873/invivo.12281 · Cited by 29
Egami, S., Kawazoe, H., Hashimoto, H., Uozumi, R., Arami, T., Sakiyama, N., Ohe, Y., Nakada, H., Aomori, T., Ikemura, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.618570 · Cited by 30
Aung, W. Y., Lee, C.-S., Morales, J., Rahman, H., & Seetharamu, N. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.05.006 · Cited by 31
Complications following novel therapies for non‐small cell lung cancer
Skribek, M., Rounis, K., Tsakonas, G., & Ekman, S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13445 · Cited by 28
Kobayashi, K., Suzuki, K., Hiraide, M., Aoyama, T., Yokokawa, T., Shikibu, S., Hashimoto, K., Iikura, Y., Sato, H., Sugiyama, E., et al. (2020) · Oncology · doi:10.1159/000505340 · Cited by 27
Self-citationEfficacy and immune-related adverse event associations in avelumab-treated patients
Kelly, K. L., Manitz, J., Patel, M. R., D’Angelo, S. P., Apolo, A. B., Rajan, A., Kasturi, V., Speit, I., Bajars, M., Warth, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001427 · Cited by 27
Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 28
Morinaga, D., Asahina, H., Ito, S., Honjo, O., Tanaka, H., Honda, R., Yokouchi, H., Nakamura, K., Takamura, K., Hommura, F., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5889 · Cited by 28
Li, Y.-L., Zhang, Y., Jia, X., Jiang, P., Mao, Z., Liang, T. B., Du, Y., Zhang, J., Zhang, G., Niu, G., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.004 · Cited by 26
Fujisaki, T., Watanabe, S., Ota, T., Kushiro, K., Sato, Y., Takahashi, M., Ohtsubo, A., Shoji, S., Nozaki, K., Ichikawa, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704475 · Cited by 26
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28
Sugisaka, J., Toi, Y., Taguri, M., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., Suzuki, K., et al. (2019) · JMA Journal · doi:10.31662/jmaj.2019-0005 · Cited by 25
Self-citationZhang, Q., Wang, W., Yuan, Q., Li, L., Wang, Y.-C., Chi, C., & Xu, C. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04375-2 · Cited by 25
Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Hyodo, Y., Kagawa, M., Izumi, K., Oyama, M., Kawakami, S., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02406-x · Cited by 27
Park, H., Hatabu, H., Ricciuti, B., Aijazi, S. J., Awad, M. M., & Nishino, M. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109275 · Cited by 24
Siddiqui, B. A., Gheeya, J., Goswamy, R. V., Bathala, T. K., Surasi, D. S., Gao, J., Shah, A. Y., Campbell, M. T., Msaouel, P., Goswami, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002850 · Cited by 24
Liang, Y., Xu, H., Liu, F., Li, L., Lin, C., Zhang, Y., Wang, N., & Wang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1281645 · Cited by 23
Chan, K. K., Tirpack, A., Vitone, G., Benson, C., Nguyen, J., Ghosh, N., Jannat‐Khah, D., Bykerk, V. P., & Bass, A. R. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11181 · Cited by 23
Otsuka, M., Sugihara, S., Mori, S., Hamada, K., Sasaki, Y., Yoshikawa, S., & Kiyohara, Y. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15246 · Cited by 23
Metadata
- Authors
- Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., Ono, H., Domeki, Y., Terayama, K., Nakamura, A., Yamanda, S., Kimura, Y., & Honda, Y.
- Affiliations
- Sendai Kousei Hospital (JP)
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
- Corresponding author
- Sugawara, Shunichi
- ORCID
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-22
- Volume
- 23
- Issue
- 11
- Pages
- 1358-1365
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC6291330
- OpenAlex
- W2809615201
- Cited by
- 294
- References
- 33
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 54 · 2023: 46 · 2022: 32 · 2021: 50 · 2020: 47 · 2019: 34 · 2018: 2
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- immune-related adverse events, nivolumab, non-small cell lung cancer, immune checkpoint inhibitors, treatment response prediction, thyroid autoantibodies, objective response rate, progression-free survival, predictive biomarkers
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Middle Aged, Retrospective Studies, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
